These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 37245486)

  • 1. Integration of clinical sequencing and immunohistochemistry for the molecular classification of endometrial carcinoma.
    Rios-Doria E; Momeni-Boroujeni A; Friedman CF; Selenica P; Zhou Q; Wu M; Marra A; Leitao MM; Iasonos A; Alektiar KM; Sonoda Y; Makker V; Jewell E; Liu Y; Chi D; Zamarin D; Abu-Rustum NR; Aghajanian C; Mueller JJ; Ellenson LH; Weigelt B
    Gynecol Oncol; 2023 Jul; 174():262-272. PubMed ID: 37245486
    [TBL] [Abstract][Full Text] [Related]  

  • 2. p53 immunohistochemistry is an accurate surrogate for TP53 mutational analysis in endometrial carcinoma biopsies.
    Singh N; Piskorz AM; Bosse T; Jimenez-Linan M; Rous B; Brenton JD; Gilks CB; Köbel M
    J Pathol; 2020 Mar; 250(3):336-345. PubMed ID: 31829441
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Harmonized molecular classification; assessment of a single-test ProMisE NGS tool.
    Jamieson A; McConechy MK; Lum A; Leung S; Thompson EF; Senz J; Talhouk A; Huntsman DG; Bashashati A; Gilks CB; McAlpine JN
    Gynecol Oncol; 2023 Aug; 175():45-52. PubMed ID: 37321155
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Validation of a one-step genomics-based molecular classifier for endometrial carcinoma in a large Chinese population.
    Kang N; Zhang X; Wang Z; Dai Y; Lu S; Su W; Gai F; Zhu C; Shen D; Wang J
    Pathol Res Pract; 2024 Feb; 254():155152. PubMed ID: 38277742
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Comprehensive assessment of mismatch repair and microsatellite instability status in molecular classification of endometrial carcinoma].
    Liu Y; Wang YX; Sun XJ; Ting X; Wu R; Liu XD; Liu CR
    Zhonghua Fu Chan Ke Za Zhi; 2023 Oct; 58(10):755-765. PubMed ID: 37849256
    [No Abstract]   [Full Text] [Related]  

  • 6. Analysis of 108 patients with endometrial carcinoma using the PROMISE classification and additional genetic analyses for MMR-D.
    Timmerman S; Van Rompuy AS; Van Gorp T; Vanden Bempt I; Brems H; Van Nieuwenhuysen E; Han SN; Neven P; Victoor J; Laenen A; Vergote I
    Gynecol Oncol; 2020 Apr; 157(1):245-251. PubMed ID: 31980219
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Confirmation of ProMisE: A simple, genomics-based clinical classifier for endometrial cancer.
    Talhouk A; McConechy MK; Leung S; Yang W; Lum A; Senz J; Boyd N; Pike J; Anglesio M; Kwon JS; Karnezis AN; Huntsman DG; Gilks CB; McAlpine JN
    Cancer; 2017 Mar; 123(5):802-813. PubMed ID: 28061006
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinicopathologic and Genomic Analysis of
    Momeni-Boroujeni A; Dahoud W; Vanderbilt CM; Chiang S; Murali R; Rios-Doria EV; Alektiar KM; Aghajanian C; Abu-Rustum NR; Ladanyi M; Ellenson LH; Weigelt B; Soslow RA
    Clin Cancer Res; 2021 May; 27(9):2613-2623. PubMed ID: 33602681
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Interobserver Agreement in Endometrial Carcinoma Histotype Diagnosis Varies Depending on The Cancer Genome Atlas (TCGA)-based Molecular Subgroup.
    Hoang LN; Kinloch MA; Leo JM; Grondin K; Lee CH; Ewanowich C; Köbel M; Cheng A; Talhouk A; McConechy M; Huntsman DG; McAlpine JN; Soslow RA; Gilks CB
    Am J Surg Pathol; 2017 Feb; 41(2):245-252. PubMed ID: 28079598
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Correlative Assessment of p53 Immunostaining Patterns and TP53 Mutation Status by Next-Generation Sequencing in High-Grade Endometrial Carcinomas.
    Matsumoto N; Manrai P; Rottmann D; Wu X; Assem H; Hui P; Buza N
    Int J Gynecol Pathol; 2023 Nov; 42(6):567-575. PubMed ID: 36730675
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prospective Clinical Prognostication of Endometrial Carcinomas Based on Next-Generation Sequencing and Immunohistochemistry-Real-World Implementation and Results at a Tertiary Care Center.
    Davies KD; Smith LP; Guimaraes-Young A; Corr BR; Fisher CM; Guntupalli SR; Berning AA; Post MD; Pino D; Aisner DL; Wolsky RJ
    Int J Gynecol Pathol; 2024 Jul; 43(4):335-348. PubMed ID: 37922951
    [TBL] [Abstract][Full Text] [Related]  

  • 12. p53 immunohistochemistry in endometrial cancer: clinical and molecular correlates in the PORTEC-3 trial.
    Vermij L; Léon-Castillo A; Singh N; Powell ME; Edmondson RJ; Genestie C; Khaw P; Pyman J; McLachlin CM; Ghatage P; de Boer SM; Nijman HW; Smit VTHBM; Crosbie EJ; Leary A; Creutzberg CL; Horeweg N; Bosse T;
    Mod Pathol; 2022 Oct; 35(10):1475-1483. PubMed ID: 35752743
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Molecular Evaluation of Endometrial Dedifferentiated Carcinoma, Endometrioid Carcinoma, Carcinosarcoma, and Serous Carcinoma Using a Custom-Made Small Cancer Panel.
    Kobayashi Y; Kitazono I; Akahane T; Yanazume S; Kamio M; Togami S; Nohara S; Sakamoto I; Yokoyama S; Tabata K; Kobayashi H; Tanimoto A
    Pathol Oncol Res; 2021; 27():1610013. PubMed ID: 35002543
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identification of molecular subtypes for endometrial carcinoma using a 46-gene next-generation sequencing panel: a retrospective study on a consecutive cohort.
    Guo Q; Tang S; Ju X; Feng Z; Zhang Z; Peng D; Liu F; Du H; Wang J; Zhang Y; Wang G; Zhang Z; Cai S; Diao Y; Zhong Y; Wu X; Zhou X; Wen H
    ESMO Open; 2024 Oct; 9(10):103710. PubMed ID: 39288655
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeted Molecular Testing in Endometrial Carcinoma: Validation of a Clinically Driven Selective ProMisE Testing Protocol.
    Talhouk A; Jamieson A; Crosbie EJ; Taylor A; Chiu D; Leung S; Grube M; Kommoss S; Gilks CB; McAlpine JN; Singh N
    Int J Gynecol Pathol; 2023 Jul; 42(4):353-363. PubMed ID: 36731023
    [TBL] [Abstract][Full Text] [Related]  

  • 16.
    De Leo A; de Biase D; Lenzi J; Barbero G; Turchetti D; Grillini M; Ravegnini G; Angelini S; Zamagni C; Coluccelli S; Dondi G; De Iaco P; Perrone AM; Tallini G; Santini D; Ceccarelli C
    Cancers (Basel); 2021 Feb; 13(5):. PubMed ID: 33668727
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Analysis of patients with endometrial carcinoma using the ProMise classifier: a pilot study from India.
    Dahiya A; Rajadurai A; Daniel S; Sebastian A; Thomas DS; Thomas V; George R; Ram TS; Sathyamurthy A; Rebekah G; Peedicayil A; Pai R; Thomas A
    Arch Gynecol Obstet; 2024 Apr; 309(4):1499-1508. PubMed ID: 37707553
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Variability in endometrial carcinoma pathology practice: opportunities for improvement with molecular classification.
    Thompson EF; Huvila J; Jamieson A; Leung S; Lum A; Offman S; Lytwyn A; Sur ML; Hoang L; Irving J; van der Westhuizen N; Morin C; Bicamumpaka C; Azordegan N; Gougeon F; Ennour-Idrissi K; Senz J; McConechy MK; Aguirre-Hernandez R; Lui V; Kuo C; Bell C; Salisbury T; Lawson J; He E; Wang S; Chiu D; Kean S; Samouëlian V; Salvador S; Gotlieb W; Helpman L; Scott S; Wohlmuth C; Vicus D; Plante M; Talhouk A; Huntsman D; Parra-Herran C; Kinloch M; Grondin K; Gilks CB; McAlpine JN;
    Mod Pathol; 2022 Dec; 35(12):1974-1982. PubMed ID: 36241860
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Genetic and molecular subtype heterogeneity in newly diagnosed early- and advanced-stage endometrial cancer.
    Da Cruz Paula A; DeLair DF; Ferrando L; Fix DJ; Soslow RA; Park KJ; Chiang S; Reis-Filho JS; Zehir A; Donoghue MTA; Wu M; Brown DN; Murali R; Friedman CF; Zamarin D; Makker V; Mueller JJ; Leitao MM; Abu-Rustum NR; Aghajanian C; Weigelt B
    Gynecol Oncol; 2021 May; 161(2):535-544. PubMed ID: 33622519
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Clinical application of TCGA molecular classification in endometrial endometrioid carcinoma].
    Du NN; Liu Y; Ren CX; Wang YX; Du J; Yang J; Liu CR
    Zhonghua Bing Li Xue Za Zhi; 2019 Aug; 48(8):596-603. PubMed ID: 31422589
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.